Canada Markets closed

Pfizer Inc. (PFE)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
38.45+0.18 (+0.47%)
At close: 4:04PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close38.27
Open38.30
Bid38.40 x 1000
Ask38.50 x 3000
Day's Range38.16 - 38.62
52 Week Range27.88 - 40.97
Volume21,693,865
Avg. Volume31,351,885
Market Cap213.583B
Beta (5Y Monthly)0.73
PE Ratio (TTM)15.22
EPS (TTM)2.53
Earnings DateOct. 27, 2020 - Nov. 02, 2020
Forward Dividend & Yield1.52 (3.97%)
Ex-Dividend DateJul. 30, 2020
1y Target Est41.85
  • Coronavirus update: NY's Cuomo OKs sending students back to school as vaccine optimism rises
    Yahoo Finance

    Coronavirus update: NY's Cuomo OKs sending students back to school as vaccine optimism rises

    New York’s school districts will welcome students back into classrooms in the fall, Governor Andrew Cuomo announced on Friday, as the former coronavirus epicenter continues on its recovery.

  • Pfizer to make Gilead's COVID-19 treatment remdesivir
    Reuters

    Pfizer to make Gilead's COVID-19 treatment remdesivir

    Gilead is aiming to make enough of the drug by the end of the year to treat more than 2 million COVID-19 patients, and agreed to send nearly all of its remdesivir supply to the United States through September. There are also fears of shortages outside the United States, and separately on Friday, Britain's Hikma Pharmaceuticals Plc said it has started manufacturing remdesivir at its Portugal plant.

  • Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-19
    Business Wire

    Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-19

    Pfizer Inc. (NYSE: PFE) today announced a multi-year agreement with Gilead Sciences, Inc. to manufacture and supply Gilead’s investigational antiviral remdesivir, as one of multiple external manufacturing organizations supporting efforts to scale up supply of the investigational treatment for COVID-19. Under the terms of the agreement, Pfizer will provide contract manufacturing services at Pfizer’s McPherson, Kansas facility to manufacture and supply remdesivir for Gilead.